Medicover AB Series B
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. Its Healthcare Services include service outpatient and inpatient care; dental services; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness; hospital care; and preventive care services. The company's Diagnostic Servi… Read more
Medicover AB Series B (0RPS) - Net Assets
Latest net assets as of June 2025: Skr485.00 Million SEK
Based on the latest financial reports, Medicover AB Series B (0RPS) has net assets worth Skr485.00 Million SEK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr2.32 Billion) and total liabilities (Skr1.83 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr485.00 Million |
| % of Total Assets | 20.92% |
| Annual Growth Rate | 18.38% |
| 5-Year Change | 1.2% |
| 10-Year Change | 425.0% |
| Growth Volatility | 61.28 |
Medicover AB Series B - Net Assets Trend (2014–2024)
This chart illustrates how Medicover AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medicover AB Series B (2014–2024)
The table below shows the annual net assets of Medicover AB Series B from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr489.30 Million | -7.38% |
| 2023-12-31 | Skr528.30 Million | +3.43% |
| 2022-12-31 | Skr510.80 Million | -9.13% |
| 2021-12-31 | Skr562.10 Million | +16.26% |
| 2020-12-31 | Skr483.50 Million | +34.42% |
| 2019-12-31 | Skr359.70 Million | +11.05% |
| 2018-12-31 | Skr323.90 Million | +6.55% |
| 2017-12-31 | Skr304.00 Million | +207.69% |
| 2016-12-31 | Skr98.80 Million | +6.01% |
| 2015-12-31 | Skr93.20 Million | +2.98% |
| 2014-12-31 | Skr90.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medicover AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 11840000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr73.50 Million | 15.81% |
| Common Stock | Skr30.70 Million | 6.60% |
| Other Comprehensive Income | Skr-56.70 Million | -12.20% |
| Other Components | Skr417.30 Million | 89.78% |
| Total Equity | Skr464.80 Million | 100.00% |
Medicover AB Series B Competitors by Market Cap
The table below lists competitors of Medicover AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aptus Value Housing Finance India Limited
NSE:APTUS
|
$898.91 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
$899.28 Million |
|
Guangdong Sky Dragon Printing Ink Group Co Ltd
SHE:300063
|
$899.32 Million |
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
$899.32 Million |
|
Northern Data AG
PINK:NDTAF
|
$898.75 Million |
|
Alliance Material Co., Ltd.
TWO:3595
|
$898.72 Million |
|
Eastcompeace Technology Co Ltd
SHE:002017
|
$898.39 Million |
|
Foran Mining Corporation
OTCQX:FMCXF
|
$898.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicover AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 496,500,000 to 464,800,000, a change of -31,700,000 (-6.4%).
- Net income of 16,700,000 contributed positively to equity growth.
- Dividend payments of 18,000,000 reduced retained earnings.
- Other comprehensive income increased equity by 63,700,001.
- Other factors decreased equity by 94,100,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr16.70 Million | +3.59% |
| Dividends Paid | Skr18.00 Million | -3.87% |
| Other Comprehensive Income | Skr63.70 Million | +13.7% |
| Other Changes | Skr-94.10 Million | -20.25% |
| Total Change | Skr- | -6.38% |
Book Value vs Market Value Analysis
This analysis compares Medicover AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 64.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 298.27x to 64.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.66 | Skr198.20 | x |
| 2015-12-31 | Skr0.67 | Skr198.20 | x |
| 2016-12-31 | Skr0.96 | Skr198.20 | x |
| 2017-12-31 | Skr2.52 | Skr198.20 | x |
| 2018-12-31 | Skr2.40 | Skr198.20 | x |
| 2019-12-31 | Skr2.38 | Skr198.20 | x |
| 2020-12-31 | Skr3.16 | Skr198.20 | x |
| 2021-12-31 | Skr3.49 | Skr198.20 | x |
| 2022-12-31 | Skr3.19 | Skr198.20 | x |
| 2023-12-31 | Skr3.32 | Skr198.20 | x |
| 2024-12-31 | Skr3.09 | Skr198.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicover AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.80%
- • Asset Turnover: 0.98x
- • Equity Multiplier: 4.60x
- Recent ROE (3.59%) is below the historical average (6.72%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 4.85% | 1.18% | 1.35x | 3.04x | Skr-4.56 Million |
| 2015 | 8.41% | 1.80% | 1.33x | 3.51x | Skr-1.42 Million |
| 2016 | 4.64% | 0.86% | 1.19x | 4.53x | Skr-4.97 Million |
| 2017 | 6.23% | 3.22% | 1.15x | 1.68x | Skr-11.33 Million |
| 2018 | 7.70% | 3.66% | 1.10x | 1.91x | Skr-7.34 Million |
| 2019 | 7.09% | 2.66% | 0.83x | 3.21x | Skr-9.24 Million |
| 2020 | 5.76% | 2.59% | 0.90x | 2.48x | Skr-19.00 Million |
| 2021 | 19.67% | 7.39% | 0.82x | 3.25x | Skr50.04 Million |
| 2022 | 2.49% | 0.78% | 0.82x | 3.86x | Skr-35.67 Million |
| 2023 | 3.54% | 1.01% | 0.90x | 3.91x | Skr-32.05 Million |
| 2024 | 3.59% | 0.80% | 0.98x | 4.60x | Skr-29.78 Million |
Industry Comparison
This section compares Medicover AB Series B's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicover AB Series B (0RPS) | Skr485.00 Million | 4.85% | 3.78x | $898.85 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |